Jounce Therapeutics, Inc. (NASDAQ:JNCE)‘s stock had its “outperform” rating reaffirmed by Robert W. Baird in a report issued on Monday. They presently have a $30.00 target price on the stock. Robert W. Baird’s target price would indicate a potential upside of 93.55% from the company’s current price.
Several other brokerages also recently issued reports on JNCE. Cowen and Company reaffirmed a “buy” rating on shares of Jounce Therapeutics in a research report on Friday, June 9th. Zacks Investment Research downgraded Jounce Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, July 12th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Jounce Therapeutics currently has an average rating of “Buy” and a consensus target price of $23.67.
Jounce Therapeutics (NASDAQ:JNCE) opened at 15.50 on Monday. The firm has a market cap of $498.39 million and a PE ratio of 574.07. Jounce Therapeutics has a 1-year low of $14.41 and a 1-year high of $24.79. The company has a 50 day moving average price of $15.16 and a 200 day moving average price of $15.16.
Jounce Therapeutics (NASDAQ:JNCE) last posted its earnings results on Wednesday, August 9th. The company reported ($0.11) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.15) by $0.04. The business had revenue of $20.29 million for the quarter, compared to analyst estimates of $19.94 million. During the same period in the previous year, the company earned ($7.23) earnings per share. On average, equities research analysts forecast that Jounce Therapeutics will post ($0.62) earnings per share for the current year.
Large investors have recently modified their holdings of the company. Teachers Advisors LLC grew its position in shares of Jounce Therapeutics by 26.4% in the second quarter. Teachers Advisors LLC now owns 11,231 shares of the company’s stock valued at $158,000 after purchasing an additional 2,347 shares during the last quarter. ARK Investment Management LLC grew its position in shares of Jounce Therapeutics by 558.9% in the second quarter. ARK Investment Management LLC now owns 11,932 shares of the company’s stock valued at $167,000 after purchasing an additional 10,121 shares during the last quarter. Nationwide Fund Advisors grew its position in shares of Jounce Therapeutics by 203.3% in the second quarter. Nationwide Fund Advisors now owns 11,946 shares of the company’s stock valued at $168,000 after purchasing an additional 8,007 shares during the last quarter. Alliancebernstein L.P. acquired a new stake in shares of Jounce Therapeutics in the second quarter valued at about $177,000. Finally, Teachers Retirement System of The State of Kentucky grew its position in shares of Jounce Therapeutics by 180.0% in the second quarter. Teachers Retirement System of The State of Kentucky now owns 12,600 shares of the company’s stock valued at $177,000 after purchasing an additional 8,100 shares during the last quarter. 43.50% of the stock is currently owned by institutional investors.
Jounce Therapeutics Company Profile
Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.
Receive News & Ratings for Jounce Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.